Brain Pericyte-Like Cell Differentiation Protocol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating brain pericyte-like cells from human pluripotent stem cells (hPSCs) are limited, particularly in scaling and reflecting genetic contributions relevant to human disease modeling, with primary sources not being scalable and iPSC-derived pericytes lacking in expression of important genetic markers.
Innovation Solution
A method involving culturing hPSCs in E6-CSFD medium for 15 days to produce p75-NGFR+ HNK+ NCSCs, followed by sorting and re-culturing in serum-containing medium to generate brain pericyte-like cells that express markers such as CNN1, NG2, and PDGFRB but not ACTA2, enhancing BBB properties and reducing transcytosis in BMECs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primary brain pericytes are used in BBB models, then high fidelity and functional enhancement are achieved, but scalability is limited
Solution Approach 1:
The patent creates copies of primary brain pericyte functionality by differentiating hPSCs into pericyte-like cells that express the same functional markers (PDGFRβ, NG2, CNN1) and perform the same BBB-enhancing functions, thereby achieving both high fidelity and scalability
Solution Approach 2:
The patent changes the source parameter from primary tissue to hPSC-derived cells, and optimizes differentiation parameters (WNT activation, BMP inhibition, activin/nodal inhibition) to generate pericyte-like cells with matching functional characteristics, resolving the contradiction between fidelity and scalability
2Productivity
If iPSC-derived pericytes are used, then scalability is improved, but expression of important genetic markers is insufficient
Solution Approach 1:
The patent applies specific signaling pathway modulations (WNT activation, BMP inhibition, activin/nodal inhibition) during differentiation to precisely control gene expression programs, ensuring that hPSC-derived pericyte-like cells achieve accurate expression of critical markers (PDGFRβ, NG2, CNN1) while maintaining scalability
Solution Approach 2:
The patent uses marker expression profiles as feedback to validate and optimize the differentiation protocol, ensuring that the derived cells meet the required specification for marker expression before being used in BBB models
3Productivity
If hPSCs are differentiated to NCSCs and then to pericyte-like cells, then scalability and genetic relevance are achieved, but process complexity increases
Solution Approach 1:
The patent segments the differentiation process into distinct stages (hPSC to NCSC, then NCSC to pericyte-like cells) with defined duration and signaling conditions for each stage, making the complex overall process more manageable and reproducible
Solution Approach 2:
The patent systematically changes signaling parameters (WNT activation, BMP inhibition, activin/nodal inhibition) at specific time points during differentiation to guide cell fate decisions, providing a controlled approach to managing process complexity while achieving the desired cell types
Data Source
AI summary
A population of brain pericyte-like cells, wherein the cells express pericyte markers but do not express ACTA2 and wherein the cells are generated from hPSCs, is disclosed herein.